Black Diamond Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 18.23 million compared to USD 20.88 million a year ago. Basic loss per share from continuing operations was USD 0.35 compared to USD 0.57 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.145 USD | +0.74% | +32.47% | +119.22% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+119.22% | 343M | |
+16.94% | 124B | |
+16.19% | 109B | |
-7.49% | 23.84B | |
+1.98% | 22.42B | |
-14.29% | 17.5B | |
-8.03% | 16.61B | |
-37.63% | 16.43B | |
+1.96% | 13.4B | |
+25.31% | 11.47B |
- Stock Market
- Equities
- BDTX Stock
- News Black Diamond Therapeutics, Inc.
- Black Diamond Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024